There have been several reports describing a notable hyperamylasemia in patients with multiple myeloma. Such amylase-producing myelomas have been mainly described in the context of concomitant with salivary-type hyperamylasemia and with sialyl salivary-type amylase identified in a portion of those cases. Sialyl salivary-type amylase, with an abnormal anodic migration, was detected by isoamylase electrophoretic analysis. The abnormal isoamylase bands migrated toward the anode faster than the salivary isoamylase band (S 2 ). The isoamylases were showed sensitive by neuraminidase treatment and were reacted with anti-human salivary monoclonal antibody. The isoamylases could be separated from residual normal isoamylase by using gel permeation chromatography. This paper reports the clinical laboratory findings indicating of sialyl salivary-type amylase in a patient with multiple myeloma.
Electrophoresis on cellulose acetate membrane of isoamylase from the patient's serum, urine and whole saliva. The amylase activity was detected by the blue starch slurry technique. 1, patient's serum; 2, patient's urine; 3, patient's saliva; 4, control saliva from healthy subject; 5, control serum from healthy subject. P 1 and P 2 , pancreatic isoamlase; S 1 and S 2 , salivary isoamylase. The fast-migrating isoamylases, indicated by a bracket, were observed in lanes 1 and 2. The isoamylases were detected in the patient's serum and urine but not in whole saliva. (B) Electrophoretic analyses of isoamylase from the patient's serum after neuraminidase treatment. 1, patient's serum; 2, patient's serum treated with neuraminidase. 3, control serum from healthy subject. The fast migrating isoamlases, indicated by a bracket, were observed in lane 1. The abnormal isoamylases showed the electrophoretically reduced mobility to the cathodic side on the treatment with neuraminidase in lane 2. 
